A third shot at EGFR: new opportunities in cancer therapy

S Guardiola, M Varese, M Sanchez-Navarro… - Trends in …, 2019 - cell.com
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …
被引用次数：72 相关文章

A Third Shot at EGFR: New Opportunities in Cancer Therapy

S Guardiola, M Varese, M Sánchez-Navarro… - Trends in …, 2019 - Elsevier
HighlightsThe initial excitement over the efficacy of EGFR-targeted drugs (TKIs and mAbs)
has been offset by a growing number of drug-resistant mutations that invariably appear in …

[引用][C] A Third Shot at EGFR: New Opportunities in Cancer Therapy

S Guardiola, M Varese, M Sánchez-Navarro… - Trends in …, 2019 - cir.nii.ac.jp
A Third Shot at EGFR: New Opportunities in Cancer Therapy | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

A Third Shot at EGFR: New Opportunities in Cancer Therapy

S Guardiola, M Varese… - Trends in …, 2019 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

A Third Shot at EGFR: New Opportunities in Cancer Therapy.

S Guardiola, M Varese… - Trends in …, 2019 - europepmc.org
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …